Recent 8-K filings for GLSI

• December 18, 2025, 6:59 PM ET other materiality 0.15 neutral item 5.07

  Annual meeting results: all five director nominees elected; auditor ratified

  David McWilliams (7,175,656 for, 452,124 abstain), Snehal Patel (7,408,074 for), Eric Rothe (7,184,827 for), F. Joseph Daugherty (7,337,720 for), Kenneth Hallock (7,313,167 for) elected.

• July 24, 2025, 7:59 PM ET other material materiality 0.45 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  Greenwich LifeSciences dismisses RBSM, hires MaloneBailey as auditor effective July 19, 2025

  Audit committee approved dismissing RBSM LLP and engaging MaloneBailey LLP for fiscal 2025 audit.

• December 19, 2024, 6:59 PM ET other materiality 0.15 neutral item 5.07

  Greenwich LifeSciences holds 2024 annual meeting; all director nominees elected, equity plan amendment approved

  All five director nominees elected with majority support; no votes against, only abstentions and broker non-votes.

• June 17, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01

  Greenwich LifeSciences raises ~$2.5M in private placement with CEO at $14.30/share

  CEO Snehal Patel purchased 174,825 shares at $14.30 (June 12 closing price) for ~$2.5M gross proceeds.

• February 20, 2024, 6:59 PM ET other material materiality 0.45 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  Greenwich LifeSciences dismisses MaloneBailey; engages RBSM as new auditor

  Audit committee approved dismissal of MaloneBailey and engagement of RBSM on Feb 14, 2024.

• February 14, 2024, 6:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Greenwich LifeSciences expands Phase III Flamingo-01 arm to 250 patients; European sites pending

  DSMB recommended continue as is; no serious adverse events related to GLSI-100 reported to date.

• December 15, 2023, 6:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  Greenwich LifeSciences stockholders elect five directors, ratify auditor at annual meeting

  Total 8,232,391 shares voted, constituting a quorum.

• April 13, 2023, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  Greenwich LifeSciences confirms FDA review of Phase IIb data, provides Flamingo-01 trial update

  FDA reviewed Phase IIb clinical data before Flamingo-01 Phase III trial commencement.

• March 13, 2023, 7:59 PM ET other material materiality 0.30 neutral item 8.01

  Greenwich LifeSciences clarifies no exposure to Silicon Valley Bank

  Company confirms it does not hold cash deposits at Silicon Valley Bank.

• December 9, 2022, 6:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  Greenwich LifeSciences annual meeting elects all five director nominees, ratifies auditor

  All five nominees (McWilliams, Patel, Rothe, Daugherty, Hallock) elected with 8.4M-8.6M votes for each; ~818K broker non-votes.

• July 12, 2022, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  FDA removes clinical hold on Greenwich LifeSciences' Flamingo-01 Phase III trial

  FDA formally removed the clinical hold on July 11, 2022, allowing the Flamingo-01 Phase III trial to proceed.

• July 12, 2022, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01

  Greenwich LifeSciences enters $100M ATM equity offering agreement with Jefferies

  Entered Open Market Sale Agreement with Jefferies LLC for at-the-market offering of common stock up to $100M.

• July 11, 2022, 7:59 PM ET regulatory materiality 0.75 negative item 8.01

  FDA clinical hold on GLSI-100 Phase III Flamingo-01 remains; manufacturing data submitted, review ongoing

  FDA placed clinical hold on Flamingo-01 trial for GLSI-100 (GP2) in HER2/neu positive patients, citing manufacturing issues.

• December 15, 2021, 6:59 PM ET other materiality 0.10 neutral item 5.07

  Greenwich LifeSciences holds 2021 annual meeting; reelects five directors and ratifies auditor

  All five director nominees (McWilliams, Patel, Rothe, Daugherty, Hallock) elected with strong support; broker non-votes of 568,923 each.

• December 13, 2021, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Greenwich LifeSciences reports 5-year GP2 Phase IIb data: baseline immune response predicts recurrence

  22.8% of 145 patients had positive baseline DTH response to GP2; 24.2% recurrence rate over 5 years (median 99 days).

• November 10, 2021, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Greenwich LifeSciences updates corporate presentation; highlights GP2 Phase IIb data and partnership discussions

  Combined analysis of 5-year Phase IIb data shows no recurrences in HER2/neu 3+ patients receiving 6 primary injections (p=0.0338).

Materiality & sentiment trend

Max materiality 0.80 · Median 0.47 · Most common event other_material

3 positive 1 negative 12 neutral

source · GLSI on sec.gov